Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab
Allison M. Bock(Mayo Clinic), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Amrita Chauhan(Unknown), Yazeed Sawalha(Cleveland Clinic), Alex F. Herrera(City of Hope), Steven M. Bair(University of Colorado Cancer Center), Shakthi Bhaskar(Vanderbilt University Medical Center), Amy Ayers(The University of Texas MD Anderson Cancer Center), Reid W. Merryman(Harvard University), Ajay Major(University of Colorado Cancer Center), Narendranath Epperla(University of Utah), Gilles Salles(Memorial Sloan Kettering Cancer Center), Sonia Godbole(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jennifer L. Crombie(Dana-Farber Cancer Institute), Matthew A. Lunning(University of Nebraska Medical Center), Lorenzo Falchi(Memorial Sloan Kettering Cancer Center), Lei Feng(The University of Texas MD Anderson Cancer Center), Andrew Jallouk(Vanderbilt University Medical Center), Omnia Farahat(The University of Texas MD Anderson Cancer Center), Christopher R. D’Angelo(Susan Thompson Buffett Foundation)
Cited by 0
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
|Advances in Therapy|2017|603
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|484